TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06034626

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light
Description: Each MGD patient underwent three treatment sessions at three-week intervals and three follow-up examinations over the course of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3% hyaluronic acid eye drops
Description: 0.3% hyaluronic acid eye drops (Hialid; Santen, Osaka, Japan) four times a day during the study, including the follow-up period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% hyaluronic acid eye drops
Description: 0.3% hyaluronic acid eye drops (Hialid; Santen, Osaka, Japan) four times a day during the study, including the follow-up period.
Study: NCT00246012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intetumumab
Description: Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.
Study: NCT01693367

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DLS 5.0 (Dynamic locking screws)
Description: Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP) and DLS 5.0
Study: NCT00246012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intetumumab
Description: Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intetumumab
Description: Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intetumumab
Description: Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.
Study: NCT02136121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci Sp Surgical System - Robotic
Description: robotic assisted laparoscopic single-port system
Study: NCT02530606

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photoacoustic Imaging
Description: Undergo PAI
Study: NCT03910998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery
Description: Bolus of rocuronium 0.1 mg/kg at the discretion of anesthetist to keep the TOF between 1-3 out of 4 during surgery
Study: NCT00246012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intetumumab
Description: Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intetumumab
Description: Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Commercially available dacarbazine will be administered intravenously over a 60-minute period (+30 minutes/-30 minutes) and prior to the intetumumab/placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue on intetumumab alone.
Study: NCT03910998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2
Description: Bolus of rocuronium 0.1 mg/kg IV will be given during surgery for a TOF 0/4 and a PTC ≤ 2 (parameters measured every 10 minutes).
Study: NCT00246012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Commercially available dacarbazine will be administered intravenously over a 60-minute period (+30 minutes/-30 minutes) and prior to the intetumumab/placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue on intetumumab alone.
Study: NCT04047563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline along with standard treatment
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. In this arm normal saline along with standard treatment will be given for active comparison.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMZ-1620 (sovateltide) along with standard treatment
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
Study: NCT03648879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscope+Cellvizio(R) 100 microscope
Description: Patients will undergo white-light, upper endoscopy. In addition, during this endoscopy patients will undergo Confocal Endoscopic Microscopy (CEM) using the Cellvizio probe (Mauna Kea Technologies) to scan the same anatomic zones.
Study: NCT00451152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 30 mg/mL
Description: Administered by anterior juxtascleral depot (AJD) in study eye, either 0.25 mL or 0.5 mL. One injection, 24 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anecortave Acetate Vehicle
Description: Administered by anterior juxtascleral depot (AJD) in study eye, 0.5 mL. One injection, 24 months.
Study: NCT01693367

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SLS (Standard locking screw)
Description: Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP)and SLS (Standard locking screw)
Study: NCT00246012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Commercially available dacarbazine will be administered intravenously over a 60-minute period (+30 minutes/-30 minutes) and prior to the intetumumab/placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue on intetumumab alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Commercially available dacarbazine will be administered intravenously over a 60-minute period (+30 minutes/-30 minutes) and prior to the intetumumab/placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue on intetumumab alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered intravenously over a period of 2 hours (+15 minutes/-15 minutes).
Study: NCT02205086

Intervention type: OTHER
Group type: OTHER
Intervention: Diagnosis
Description: Unaided: The testers will record a differential diagnosis consisting of a list of diseases and their ranking and a prioritized list of test orders, as well as the most appropriate referral for further evaluation and treatment of the patient.~Aided: Then testers will enter the case into diagnostic decision support software and after getting advice from the software, the testers will record the same information as in Unaided, but allowing for the possibility that responses could differ as a result of using the software.
Study: NCT04364789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TT-00920
Description: Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TT-00920
Description: Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TT-00920
Description: Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TT-00920
Description: Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TT-00920
Description: Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TT-00920
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Tablets
Study: NCT00272935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenestin 0.3 mg Tablets
Description: 1 tablet daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily
Study: NCT03496363

Intervention type: DIAGNOSTIC_TEST
Intervention: TSH , T4
Description: Thyroid stimulating hormone
Study: NCT03176797

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver MRI
Description: Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.
Study: NCT02069496

Intervention type: BIOLOGICAL
Intervention: Arepanrix®
Description: Injected according to the prescribing information in the locally approved label by the authorities.
Study: NCT00564954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dex-methylphenidate hydrochloride extended-release (Focalin XR)
Description: 20 mg capsule orally once a day for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally once a day for 7 days
Study: NCT03044015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community based integrated strategy for secondary prevention of OF
Description: Educational programme on pharmacological treatment, diet recommendations, physical activity programme on OF prevention in primary care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: as usual
Study: NCT03532672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Fasting
Description: The volunteers will fast overnight (10 hours) and breakfast will be offered (bread, butter, ham and industrialized fruit juice). The participants will fast for another 10 hours during daily activities.
Study: NCT02065622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01919697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plecanatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plecanatide
Study: NCT03346018

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of aqueous humor and plasma samples
Description: The collected samples will be analyzed as follow:~1. Determination of the concentration of various cytokines, chemokines and groeth factors in aqueous humor and in the plasma.~2. Analysis of the mononuclear cells ( T helper lymphocytes CD3+ and CD4+, T cytotoxic lymphocytes CD3+ CD8+, B lymphocytes CD19+, Natural killer lymphocytes CD56+ and CD3- and monocytes CD14+) present in the aqueous humor by cytofluorimetry.~3. Evaluation of the presence of anti-human HSP70 antibodies in plasma samples by Western blot immunoprecipitation assays.~4. Whenever possible (adequate number of cells), in vitro stimulation of mononuclear cells presence in aqueous humor with epitopes from tuberculosis mycobacterium antigens and the analysis of cytokines production in the supernatants.

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of aqueous humor and plasma samples
Description: The collected samples will be analyzed as follow:~1. Determination of the concentration of various cytokines, chemokines and groeth factors in aqueous humor and in the plasma.~2. Analysis of the mononuclear cells ( T helper lymphocytes CD3+ and CD4+, T cytotoxic lymphocytes CD3+ CD8+, B lymphocytes CD19+, Natural killer lymphocytes CD56+ and CD3- and monocytes CD14+) present in the aqueous humor by cytofluorimetry.~3. Evaluation of the presence of anti-human HSP70 antibodies in plasma samples by Western blot immunoprecipitation assays.~4. Whenever possible (adequate number of cells), in vitro stimulation of mononuclear cells presence in aqueous humor with epitopes from tuberculosis mycobacterium antigens and the analysis of cytokines production in the supernatants.
Study: NCT06616662

Intervention type: PROCEDURE
Intervention: MAF
Description: use mucosal advancement flap to treat PAF

Intervention type: PROCEDURE
Intervention: LIFT
Description: use LIFT surgery for treating PAF
Study: NCT03123887

Intervention type: OTHER
Intervention: salvage therapy
Description: VDC(L)P regimen or High-dose cytarabine based regimen or High-dose methotrexate based regimen or Hyper-CVAD regimen or FLAG (Flu, Ara-C, G-CSF) ± anthracyclines based regimen or Repeated original induction regimen or VDP or other
Study: NCT02696941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500mg once daily and titrated weekly to a dose of 1000mg twice daily for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: SGLT2 inhibitor has been recommended to be started as part of routine clinical care
Study: NCT00670033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution (new formulation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost ophthalmic solution, 0.004%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Inactive ingredients used as a placebo
Study: NCT00793117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: packing
Description: packing in middle meatus for duration of 5 day
Study: NCT03802617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR13A9
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR13A9
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR13A9
Description: Intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration
Study: NCT03995017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rucaparib
Description: Rucaparib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab intravenous solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Ramucirumab intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab intravenous solution
Study: NCT03297567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: verbal guidance and a booklet
Description: Patients allocated to the intervention group will receive verbal instruction from the researchers on the importance and benefits of movement during hospital stay, as well as what they should do to increase the level of physical activity. These patients will receive the same guidelines through a playable, easy-to-understand and inexpensive booklet developed by the researchers themselves in PowerPoint 2016 (Microsoft) in order to remedy any doubt or forgetfulness during the hospitalization period
Study: NCT02065622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02207699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzonatate 200 mg
Description: 2 benzonatate 100 mg perles and 6 placebo perles give by mouth once
Study: NCT01573533

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be infused intravenously on Day 1 and Day 15 at a dose of 375 mg/m2 up to a maximum of 1000mg per dose in children and at a dose of 1000 mg on Day 1 and Day 15 in adults.
Study: NCT03658473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 550 mg naproxen + 300 mg rebamipide + 20 mg rabeprazole.
Description: Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 550 mg naproxen + placebo + 20 mg rabeprazole
Description: Oral administration of 550 mg naproxen 2x daily + placebo of rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 550 mg naproxen + 300 mg rebamipide + placebo
Description: Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + placebo of rabeprazole 1x daily over 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 550 mg naproxen + placebo + placebo
Description: Oral administration of 550 mg naproxen 2x daily + placebo 2x daily + placebo of rabeprazole 1x daily over 7 days.
Study: NCT01868763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemedical devices (weighing machine and step counter)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemedical devices (weighing machine and step counter)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: care calls once per week for 12 weeks
Study: NCT00406588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa (Pardoprunox)
Description: 12-42mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo
Study: NCT02207699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzonatate 800 mg
Description: 8 benzonatate 100 mg perles given by mouth once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg
Description: 1 moxifloxacin 400 mg tablet given by mouth once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 placebo perles given by mouth once
Study: NCT02108951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib 150mg hard gelatin capsules taken orally
Study: NCT03391687

Intervention type: DIAGNOSTIC_TEST
Intervention: Amylase Test
Description: body fluid amylase will be tested after radical gastrectomy in scheduled interval
Study: NCT02678234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol, phenylephrine HCl, and vitamin C
Description: One sachet is provided for each participant randomized to the Theraflu Aktiv powder for oral solution
Study: NCT01787643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Height-Adjustable Desk Intallation in Office
Study: NCT02782871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneupac VR1
Description: A portable mechanical ventilator/resuscitator for medical personnel in the hospital, ambu-lance, fire, and police services.
Study: NCT00276978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Addition of Aripiprazole 10 mg to concurrent medication
Study: NCT00379223

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vitrectomy with radial optic neurotomy
Study: NCT01253044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy
Description: Present Centered Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
Study: NCT03870126

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flavored beverage
Description: Consume one beverage at the beginning of each visit of the cross-over sequence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavored beverage
Description: Consume one beverage at the beginning of each visit of the cross-over sequence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavored beverage
Description: Consume one beverage at the beginning of each visit of the cross-over sequence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavored beverage
Description: Consume one beverage at the beginning of each visit of the cross-over sequence
Study: NCT03273205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: This group gets a real stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: This group gets a sham stimulation